Viral hepatitis A, B, C; herpetic infection; cytomegalovirus infection, as part of the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis); as part of the complex therapy of urogenital and respiratory chlamydia; treatment and prevention of influenza and acute respiratory viral infections.
Out of stock
Lavomax №3 The composition of the drug:
active substance: tilorone;
1 tablet contains tilorone 125 mg;
excipients: magnesium carbonate basic aqueous, povidone, calcium stearate;
shell composition: sucrose, povidone, copovidone, magnesium basic carbon dioxide, titanium dioxide (E 171), colloidal anhydrous silica, tropeolin O, macrogol 6000, white soft paraffin, liquid paraffin, talc.
Lavomax №3 Dosage form
Coated tablets, yellow to orange, round. The core of the tablet is orange.
Name and location of the manufacturer. OJSC NIZHPHARM. Russian Federation, 603950, Nizhny Novgorod, GSP-459, st. Salganska, 7.
Immunostimulants. PBX code L03A X.
Tylorone stimulates the formation of α-, β- and γ-interferons in the body. The main producers of interferon in response to Lavomax are intestinal epithelial cells, hepatocytes, T-lymphocytes and neutrophils. After ingestion, the maximum production of interferon is determined in the sequence of intestine-liver-blood in 4-24 hours. Lavomax has an immunomodulatory and antiviral effect, stimulates bone marrow stem cells, depending on the dose enhances antibody production, reduces the degree of immunosuppression, restores the ratio of T-helpers / T-suppressors. Effective against various viral infections, including those caused by influenza viruses and other pathogens of acute respiratory viral infections, hepatitis and herpes. The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, resulting in inhibition of virus reproduction.
After ingestion, tylorone is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug is bound to plasma proteins.
The drug is excreted almost unchanged in the feces (70%) and urine (9%). The half-life (T () is 48 hours. The drug is not biotransformed and does not accumulate in the body.
Lavomax №3 Indications for use
Viral hepatitis A, B, C; herpes infection; cytomegalovirus infection, as part of complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis); as a part of complex therapy of urogenital and respiratory chlamydia; treatment and prevention of influenza and acute respiratory viral infections.
Contraindication. Hypersensitivity to the drug. Sucrose / isomaltose deficiency, fructose intolerance, glucose-galactose malabsorption (the drug contains sucrose).
Lavomax №3 Special caveats
Use during pregnancy or breastfeeding. During pregnancy or breastfeeding, the drug is contraindicated. Due to the embryotoxic effects of tilorone, women should use reliable contraception during treatment with Lavomax.
Ability to influence the speed of reaction when driving a car or working with other mechanisms. Does not affect.
Do not apply.